Vimarsana
Biggest News Aggregation in the World

Suspected Moderate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Suspected Moderate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Suspected Moderate Today - Breaking & Trending Today

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis - Vimarsana News

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Published: February 4, 2024

Bexotegrast at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320...

Source: marketscreener.com
Related Topics:
United StatesGideon HirshfieldClin Gastroenterol HepatolKrisv KowdleyChristopher KeenanTerry HornerWashington State UniversityElsons Floyd College Of MedicineCorporate CommunicationsDrug AdministrationLiver InstituteEuropean Medicines AgencyPliant Therapeutics IncUniversity Of TorontoClinical Development NextGlobenewswire IncEnhanced Liver FibrosisChief Medical OfficerWell ToleratedSerious AdverseDemonstrated Antifibrotic ActivitySuspected ModerateSevere Liver FibrosisItch Numerical Rating ScaleLiver Institute Northwest
Pliant Therapeutics Announces Positive Safety and - Vimarsana News

Pliant Therapeutics Announces Positive Safety and

Published: February 4, 2024

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns...

Source: globenewswire.com
Related Topics:
United StatesGideon HirshfieldChristopher KeenanClin Gastroenterol HepatolTerry HornerKrisv KowdleyUniversity Of TorontoCorporate CommunicationsLiver InstituteClinical Development NextDrug AdministrationEuropean Medicines AgencyPliant Therapeutics IncEnhanced Liver FibrosisChief Medical OfficerWell ToleratedSerious AdverseMayo ScoreDemonstrated Antifibrotic ActivitySuspected ModerateSevere Liver FibrosisItch Numerical Rating ScaleLiver Institute NorthwestWashington StateDevelopment Next
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis - Vimarsana News

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Published: September 26, 2023

Bexotegrast was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis ...

Source: marketscreener.com
Related Topics:
United StatesChristopher KeenanClin Gastroenterol HepatolDrug AdministrationUniversity Of Miami School MedicinePliant Therapeutics IncEuropean Medicines AgencyCorporate CommunicationsEnhanced Liver FibrosisChief Medical OfficerMayo ScoreDemonstrated Antifibrotic ActivitySuspected ModerateSevere Liver FibrosisItch Numerical Rating ScaleCynthia LevyMiami SchoolPrimary SclerosingTuesday SeptemberPliant TherapeuticsFast Track DesignationOrphan Drug DesignationPrivate Securities Litigation Reform ActFinancial ConditionQuarterly Report
Pliant Therapeutics Announces Positive Safety and - Vimarsana News

Pliant Therapeutics Announces Positive Safety and

Published: September 26, 2023

Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events ...

Source: globenewswire.com
Related Topics:
United StatesChristopher KeenanClin Gastroenterol HepatolUniversity Of Miami School MedicinePliant Therapeutics IncCorporate CommunicationsDrug AdministrationEuropean Medicines AgencyEnhanced Liver FibrosisChief Medical OfficerMayo ScoreDemonstrated Antifibrotic ActivitySuspected ModerateSevere Liver FibrosisItch Numerical Rating ScaleCynthia LevyMiami SchoolPrimary SclerosingTuesday SeptemberPliant TherapeuticsFast Track DesignationOrphan Drug DesignationPrivate Securities Litigation Reform ActFinancial ConditionQuarterly Report